A Canadian study evaluated the pattern of metastatic disease in 180 triple-negative, including estrogen and progesterone receptor- and HER2/neu-negative, BC patients who were compared with additional subgroups of BC (N = 1,428). Here, ERBB2 is linked to breast cancer.